Hudson Bay Capital Management’s Psyence Biomedical PBM Stock Holding History

Hudson Bay Capital Management’s Portfolio PBM Stock Details PBM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,629	Closed	-$744K	–	1493
2024 Q4	$744K	Buy	+7,629	New	+$1.82M	﹤0.01%	789

Other funds holding PBM

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

SFFS

Stonehage Fleming Financial Services St. Helier, Jersey $2.75B AUM 13.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hudson Bay Capital Management's PBM Position: Q1 2025 in Review

Hudson Bay Capital Management sold out of Psyence Biomedical (PBM) in Q1 2025, closing a stake of 7,629 shares — an estimated $744K sold.

Hudson Bay Capital Management first reported a position in PBM in Q4 2024 and held it in 1 quarter. The position peaked at $744K in Q4 2024. 8 funds tracked by Wall St. Rank hold PBM as of Q1 2025.

Hudson Bay Capital Management reported no remaining Psyence Biomedical position as of Q1 2025 after selling out during the quarter.
Hudson Bay Capital Management sold 7,629 Psyence Biomedical shares in Q1 2025, an estimated $744K.
Hudson Bay Capital Management first reported a position in Psyence Biomedical in Q4 2024 and held it in 1 quarter.
Hudson Bay Capital Management's Psyence Biomedical position peaked at $744K in Q4 2024.
8 funds tracked by Wall St. Rank held Psyence Biomedical as of Q1 2025.

Based on Hudson Bay Capital Management's 13F filing for Q1 2025, filed 14 May 2025.